Sugi Predict

Sugi Predict / Targets / DHCR7

DHCR7

7-dehydrocholesterol reductase · Q9UBM7 · DHCR7 on Sugi Atlas →

7,498 patent compounds predicted against DHCR7, 5,557 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL640570 SCHEMBL640570 0.58 5/20
SCHEMBL640174 SCHEMBL640174 0.52 5/20
SCHEMBL3143811 SCHEMBL3143811 0.49 5/20
SCHEMBL4001419 SCHEMBL4001419 0.49 5/20
SCHEMBL4108812 SCHEMBL4108812 0.49 5/20
SCHEMBL4119445 SCHEMBL4119445 0.47 5/20
SCHEMBL3336572 SCHEMBL3336572 0.40 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL641578) 0.39 5/20
SCHEMBL3140025 SCHEMBL3140025 0.50 4/20
SCHEMBL3148752 SCHEMBL3148752 0.50 4/20
SCHEMBL3151991 SCHEMBL3151991 0.47 4/20
SCHEMBL3042454 SCHEMBL3042454 0.81 3/20
SCHEMBL3052036 SCHEMBL3052036 0.80 3/20
SCHEMBL3504140 SCHEMBL3504140 0.79 3/20
Enclomiphene Enclomiphene (SCHEMBL34893) 0.75 3/20
Zuclomiphene Zuclomiphene (SCHEMBL34894) 0.75 3/20
Zuclomiphene Zuclomiphene (SCHEMBL402392) 0.73 3/20
Enclomiphene Enclomiphene (SCHEMBL407458) 0.73 3/20
SCHEMBL3054533 SCHEMBL3054533 0.70 3/20
SCHEMBL3505441 SCHEMBL3505441 0.70 3/20

Clinical trials — most relevant to DHCR7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
LDL Receptor Under Ezetimibe and Simvastatin PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis PHASE2COMPLETED
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) PHASE2UNKNOWN
Vitamin D Intervention Trial in Healthy Chinese, Phase II PHASE1COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Study of Smith-Lemli-Opitz Syndrome nanCOMPLETED
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome nanWITHDRAWN
Effect of Bariatric Surgery on Bile Acid Homeostasis nanCOMPLETED
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism nanRECRUITING
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum nanCOMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health nanUNKNOWN
Genetic Study of Sitosterolemia nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Exome Sequencing in Autistic Spectrum Disorder nanCOMPLETED
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy nanRECRUITING
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
STATIC - Statin Termination in Cancer nanRECRUITING
Regulation of Sterol Homeostasis nanCOMPLETED
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease nanACTIVE_NOT_RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DHCR7 binder may also engage these)

ProteinNameSimilarity
O88455 — 1.000 O88455 →
Q9Z2Z8 — 1.000 Q9Z2Z8 →
Q7ZXH1 — 1.000 Q7ZXH1 →
Q7SXF1 — 0.998 Q7SXF1 →
Q4WW43 — 0.996 Q4WW43 →
Q6P4M0 — 0.996 Q6P4M0 →
Q5E9J5 — 0.995 Q5E9J5 →
P38670 — 0.986 P38670 →
Q4WJ59 — 0.984 Q4WJ59 →
P78575 — 0.984 P78575 →
Q09195 — 0.983 Q09195 →
P36209 — 0.982 P36209 →
Q4WJJ9 — 0.982 Q4WJJ9 →
I1RZZ3 — 0.981 I1RZZ3 →
B0XUW3 — 0.980 B0XUW3 →
C0NLX2 — 0.979 C0NLX2 →
C5FZ62 — 0.979 C5FZ62 →
Q4WKA5 — 0.979 Q4WKA5 →
I1RR90 — 0.978 I1RR90 →
O08984 — 0.978 O08984 →
Q01447 — 0.977 Q01447 →
Q0CVD7 — 0.977 Q0CVD7 →
B2B2N5 — 0.977 B2B2N5 →
A0A1D8PJ25 — 0.977 A0A1D8PJ25 →
I1RF79 — 0.976 I1RF79 →
O12947 — 0.976 O12947 →
Q2UDE5 — 0.976 Q2UDE5 →
B6HJA3 — 0.976 B6HJA3 →
P25340 — 0.976 P25340 →
Q2H0U8 — 0.976 Q2H0U8 →